Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.43 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2571280 | 0.87 | SRD5A1 (0.48) | CHRNA7SRD5A1OPRM1OPRD1OPRK1 | |
| SCHEMBL2572769 | 0.87 | SRD5A1 (0.48) | CHRNA7SRD5A1OPRM1OPRD1OPRK1 | |
| SCHEMBL2571011 | 0.87 | SRD5A1 (0.48) | CHRNA7SRD5A1OPRM1OPRD1OPRK1 | |
| SCHEMBL6494545 | 0.87 | CHRNA7 (0.46) | CHRNA7OPRM1OPRD1OPRK1 | |
| SCHEMBL24570919 | 0.86 | SRD5A1 (0.44) | CHRNA7SRD5A1OPRM1OPRD1OPRK1 | |
| SCHEMBL13860426 | 0.86 | TAAR1 (0.43) | SRD5A1 | |
| SCHEMBL22494227 | 0.86 | SRD5A1 (0.41) | CHRNA7SRD5A1OPRM1OPRD1OPRK1 | |
| SCHEMBL31158034 | 0.86 | SRD5A1 (0.44) | CHRNA7SRD5A1OPRM1OPRD1OPRK1 | |
| SCHEMBL31151861 | 0.86 | SRD5A1 (0.41) | CHRNA7SRD5A1OPRM1OPRD1OPRK1 | |
| SCHEMBL30861566 | 0.86 | TAAR1 (0.43) | SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022140555-A1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2022-06-30 | — | — | WO | disclosed |
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| EP-1708698-A1 | 3-(4-PIPERIDINE-1YLMETHYL-PHENYL)-PROPION ACID-PHENYLAMIDE-DERIVATIVES AND RELATED COMPOUNDS USED IN THE FORM OF MCH ANTAGONISTS (MELANINE CONCENTRATING HORMONE) FOR TREATING EATING DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005063239-A9 | 3-(4-PIPERIDINE-1YLMETHYL-PHENYL)-PROPION ACID-PHENYLAMIDE-DERIVATIVES AND RELATED COMPOUNDS USED IN THE FORM OF MCH ANTAGONISTS (MELANINE CONCENTRATING HORMONE) FOR TREATING EATING DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2006-03-09 | — | — | WO | disclosed |
| US-20050267093-A1 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
| WO-2005063239-A1 | 3-(4-PIPERIDINE-1YLMETHYL-PHENYL)-PROPION ACID-PHENYLAMIDE-DERIVATIVES AND RELATED COMPOUNDS USED IN THE FORM OF MCH ANTAGONISTS (MELANINE CONCENTRATING HORMONE) FOR TREATING EATING DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267093-A1 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, MC4R, MCHR2 | CHRNA7 1785/4885SRD5A1 3878/4885MBTD1 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.